A Phase 3 interventional study of MT-1186 in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2020, is one of 8 in phase 3, and was the 12th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:
National Center of Neurology and Psychiatry, Japan · Sites in Japan
Ages 20+
Regeneron Pharmaceuticals · Sites in Japan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 10
First in 2007; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 136 across the 20 interventional studies, 24 across the 1 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 21 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 6 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Amyotrophic Lateral Sclerosis with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral Edaravone administered once daily for 10 days out of 14, followed by a 14-day drug- free period
Drug: MT-1186
Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.
Also known as: Oral Edaravone
Number of Events of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESEAs, TEAEs Leading to Discontinuation, Any TEAEs Leading to Death
AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized. - Severe TEAEs: TEAEs which was classified as severe for the severity were analyzed. The severity of TEAEs was classified according to the following criteria: Mild (The event is transient and easily tolerated by the subject.), Moderate: The event causes discomfort and interferes with the subject's general condition.), and Severe (The event causes considerable interference with the subject's general condition and may be incapacitating.) - TESAEs, which is Serious TEAEs, is the TEAEs when the patients outcome is death, life-threatening, hospitalization, or disability or permanent damage.
Time frame: up to 96 Weeks
Number of Subjects of Treatment Emergency Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Severe TEAEs, TESAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized.
Time frame: up to 96 Weeks
Change From Baseline of ALS Functional Rating Scale-Revised (ALSFRS-R) at Week 96
ALS Functional Rating Scale- Revised (ALSFRS-R). The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.
Time frame: Baseline to Week 96
Number of Events of Death, Tracheostomy, or Permanent Assisted Mechanical Ventilation
Time frame: up to 96 Weeks
| Milestone | MT-1186 |
|---|---|
| Started | 124 |
| Completed | 49 |
| Not completed | 75 |
| Withdrew: Adverse event | 31 |
| Withdrew: Death | 1 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Physician decision | 7 |
| Withdrew: Withdrawal by subject | 21 |
| Withdrew: Switched to commercial oral edaravon etc. | 12 |
AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized. - Severe TEAEs: TEAEs which was classified as severe for the severity were analyzed. The severity of TEAEs was classified according to the following criteria: Mild (The event is transient and easily tolerated by the subject.), Moderate: The event causes discomfort and interferes with the subject's general condition.), and Severe (The event causes considerable interference with the subject's general condition and may be incapacitating.) - TESAEs, which is Serious TEAEs, is the TEAEs when the patients outcome is death, life-threatening, hospitalization, or disability or permanent damage.
| events | MT-1186 |
|---|---|
| Number of TEAEs | 616 |
| Number of ADRs | 17 |
| Number of severe TEAEs | 60 |
| Number of TESAEs | 75 |
| Number of TEAEs leading to discontinuation | 35 |
| Number of TEAEs leading to death | 19 |
AEs that occurred on or after the first dose in the MT-1186-A03 will be summarized, which implies AE that occurred during MT-1186-A01 will not be summarized.
| Participants | MT-1186 |
|---|---|
| Number of TEAEs | 113 |
| Number of ADRs | 12 |
| Number of severe TEAEs | 44 |
| Number of TESEAs | 52 |
| Number of TEAEs leading to discontinuation | 28 |
| Number of TEAEs leading to death | 19 |
ALS Functional Rating Scale- Revised (ALSFRS-R). The ALSFRS-R is rating scale (ratings 0 = can't do, to 4 = normal ability) used to determine participants' assessment of their capability and independence in 12 functional activities.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over up to 96 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MT-1186 | 19/124 (15.3%) | 52/124 (41.9%) | 70/124 (56.5%) |
| Event | MT-1186 |
|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 13/124 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 9/124 |
| DysphagiaGastrointestinal disorders | 7/124 |
| Amyotrophic lateral sclerosisNervous system disorders | 6/124 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/124 |
| PneumoniaInfections and infestations | 3/124 |
| COVID-19Infections and infestations | 3/124 |
| GastrostomySurgical and medical procedures | 2/124 |
| Pneumonia staphylococcalInfections and infestations | 1/124 |
| Urinary tract infectionInfections and infestations | 1/124 |
| Event | MT-1186 |
|---|---|
| FallInjury, poisoning and procedural complications | 20/124 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 18/124 |
| ConstipationGastrointestinal disorders | 16/124 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/124 |
| COVID-19Infections and infestations | 11/124 |
| InsomniaPsychiatric disorders | 9/124 |
| DysphagiaGastrointestinal disorders | 8/124 |
| Urinary tract infectionInfections and infestations | 8/124 |
| AnxietyPsychiatric disorders | 8/124 |
| NauseaGastrointestinal disorders | 7/124 |
| Age, Continuous(years) | MT-1186 |
|---|---|
| Mean | 59.0 ± 10.1 |
| Age, Customized(Participants) | MT-1186 |
|---|---|
| Adults (18-64 years) | 84 |
| From 65 to 84 years | 40 |
| Sex: Female, Male(Participants) | MT-1186 |
|---|---|
| Female | 41 |
| Male | 83 |
| Ethnicity (NIH/OMB)(Participants) | MT-1186 |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 118 |
| Unknown or Not Reported | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2020 to primary completion in Aug 2023, 33 months.
Results were first posted in Aug 2024, 1 year after primary completion.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 33 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →